Syk

Cat. No.

A30868

CAS No.

1370261-98-5

PRT062607 acetate

Synonyms: P505-15 acetate; PRT-2607 acetate; BIIB-057 acetate

PRT062607 acetate is a potent Syk inhibitor with an IC50 of 1 nM, designed for oral administration. This compound effectively inhibits inflammatory pathways and induces apoptosis, demonstrating significant antitumor activity in tumor xenograft mouse models. It serves as a valuable tool in cancer research and the study of Syk-mediated signaling.

Cat. No.

A31781

CAS No.

3032567-93-1

PRT-060318 dihydrochloride

Synonyms: PRT318 dihydrochloride

PRT-060318 dihydrochloride is a selective and potent inhibitor of the tyrosine kinase Syk, exhibiting an IC50 of 3 nM. This compound effectively suppresses B cell activation and migration in chronic lymphocytic leukemia (CLL) and induces apoptosis in these cells. Additionally, PRT-060318 dihydrochloride has demonstrated the ability to prevent Heparin-induced thrombocytopenia and thrombosis in transgenic mouse models, making it a valuable tool for research in CLL and thrombus formation.

Cat. No.

A33291

CAS No.

1398695-47-0

GSK2646264

GSK2646264 is a potent and selective inhibitor of spleen tyrosine kinase (SYK), exhibiting a pIC50 value of 7.1. This compound also shows inhibitory activity against several other kinases, including LCK, LRRK2, GSK3β, JAK2, VEGFR2, and Aurora kinases, with varying pIC50 values. Due to its ability to penetrate the epidermis and dermis, GSK2646264 is potentially valuable for research applications in dermatological conditions and immune responses.

Cat. No.

A33329

CAS No.

2228989-14-6

Gusacitinib hydrochloride

Synonyms: ASN-002 hydrochloride

Gusacitinib hydrochloride is a potent dual inhibitor of SYK and JAK kinases, demonstrating IC50 values of 5 nM, 46 nM, 4 nM, 11 nM, and 8 nM for SYK, JAK1, JAK2, JAK3, and TYK2, respectively. This compound effectively suppresses critical inflammatory pathways linked to the pathogenesis of atopic dermatitis. Gusacitinib hydrochloride is suitable for research applications involving chronic hand eczema and various cancers, including basal cell carcinoma.

Cat. No.

A33430

CAS No.

2737326-28-0

SYK/JAK-IN-1

SYK/JAK-IN-1 is a dual inhibitor targeting SYK and JAK2, exhibiting IC50 values of less than 5 nM for both kinases. This compound demonstrates significant anti-inflammatory and anti-proliferative activities, making it a valuable tool for research involving hematological malignancies and autoimmune disorders. Its potent inhibition profile allows for the exploration of signaling pathways associated with SYK and JAK2, facilitating studies in cancer biology and immunology.

Cat. No.

A33454

CAS No.

1620142-65-5

R-348 choline

Synonyms: R-932348 choline

R-348 choline is a potent, orally active inhibitor of Janus kinase 3 (JAK3) and spleen tyrosine kinase (Syk). This compound effectively reduces the expression levels of pro-inflammatory cytokines, including interferon-gamma (IFN-γ), interleukin-6 (IL-6), and interleukin-10 (IL-10). R-348 choline is primarily utilized in research related to acute cardiac allograft rejection and other autoimmune conditions where JAK3 and Syk signaling play critical roles.

Cat. No.

A34941

CAS No.

1630203-25-6

TOP1362

TOP1362 is a potent inhibitor targeting P38-α and Syk kinases, with Kd values of 26 nM and 18 nM, respectively. The compound demonstrates an IC50 of 14 nM in Src kinase activity assays, showcasing its efficacy in inhibiting P38-α, Src, and Syk. TOP1362 is applicable in research focused on dry eye syndrome and related pathways.

Cat. No.

A35132

CAS No.

1429038-15-2

TAS05567

TAS05567 is a highly selective, ATP-competitive inhibitor of Syk, exhibiting an IC50 of 0.37 nM. This compound demonstrates potent inhibition of Syk alongside four other kinases (FLT3, JAK2, KDR, and RET) at IC50 values of 10 nM, 4.8 nM, 600 nM, and 29 nM, respectively. TAS05567 is suitable for research applications related to humoral immune-mediated inflammatory conditions, including various autoimmune and allergic diseases.

Cat. No.

A36713

CAS No.

1240390-27-5

GSK143

GSK143 is a highly selective inhibitor of spleen tyrosine kinase (SYK) with an oral bioavailability and a pIC50 of 7.5. It effectively inhibits phosphorylated Erk (pErk) with a pIC50 of 7.1. GSK143 demonstrates significant anti-inflammatory properties and has been shown to reduce immune cell recruitment in the intestinal muscularis in murine models, making it a valuable tool for research in inflammatory diseases and immune response modulation.

Cat. No.

A36992

CAS No.

577-38-8

Flavanomarein

Flavanomarein is a potent inhibitor of Syk and NF-κB p65, as well as a modulator of TGF-β1/Smad signaling pathways. This compound exhibits cytoprotective, anti-inflammatory, and antioxidant activities, enhancing AKT phosphorylation while regulating key proteins such as PKC-δ, P85α, PKC-β1, Sirt1, Bcl-2, and ICAD. Flavanomarein also inhibits the nuclear translocation of NF-κB p65 and modulates epithelial-mesenchymal transition (EMT) markers, promoting proliferation in HK-2 cells and protecting neuronal cells from 6-OHDA-induced neurotoxicity. This compound is valuable for research on Parkinson's disease and diabetic nephropathy.

Cat. No.

A45840

CAS No.

726695-51-8

Syk Inhibitor II

Syk Inhibitor II is a highly selective, ATP-competitive inhibitor of spleen tyrosine kinase (Syk) with an IC50 of 41 nM. It effectively inhibits 5-hydroxytryptamine (5-HT) release from rat basophilic leukemia (RBL) cells, demonstrating an IC50 of 460 nM. This compound exhibits a lower potency against other kinases, making it a valuable tool for studying Syk-mediated signaling pathways and exploring its potential in anti-allergic research applications.

Cat. No.

A46064

CAS No.

227449-73-2

Syk Inhibitor II dihydrochloride

Syk Inhibitor II dihydrochloride is a highly selective, ATP-competitive inhibitor of Spleen Tyrosine Kinase (Syk) with an IC50 of 41 nM. It effectively inhibits 5-HT release from rat basophilic leukemia (RBL) cells, demonstrating an IC50 of 460 nM. This compound exhibits reduced potency against other kinases, making it a valuable tool for research applications in immunology and allergy research, particularly in studies investigating Syk's role in signaling pathways associated with allergic responses.

Cat. No.

A84722

CAS No.

1312534-69-2

MRL-SYKi

MRL-SYKi is a selective chemical probe targeting spleen tyrosine kinase (SYK). It demonstrates potent binding to gain-of-function variants of SYK, with IC50 values of 2.1 nM for SYK(S550Y), 14 nM for SYK(S550F), and 4.6 nM for SYK(P342T) in digitonin-permeabilized cell assays. MRL-SYKi effectively inhibits catalytic activity, achieving IC50 values of 63 nM and 95 nM for SYK(S550F) and SYK(P342T) respectively in phospho-specific assays. This compound is valuable for advancing research on inflammation and related signaling pathways.

Cat. No.

A84723

CAS No.

1415792-84-5

Sovleplenib

Synonyms: HMPL-523

Sovleplenib is a selective Spleen Tyrosine Kinase (SYK) inhibitor with an IC50 of 25 nM, demonstrating high potency and oral bioavailability. This compound exhibits significant anti-tumor activity and is useful in the research of immune thrombocytopenia (ITP). Its targeted mechanism makes it a valuable tool for studying the roles of SYK in various immune-mediated conditions.

Cat. No.

A84724

CAS No.

2932264-95-2

Syk-IN-4

Syk-IN-4 is a selective, orally bioavailable inhibitor of SYK, exhibiting an IC50 of 0.31 nM. This compound demonstrates significant potential in modulating immune responses and is being investigated for its therapeutic applications in autoimmunity and hematological malignancies. Syk-IN-4 serves as a valuable tool for researchers exploring the role of SYK in disease progression and treatment strategies.

Cat. No.

A84725

CAS No.

1703788-21-9

Cevidoplenib

Synonyms: SKI-O-703

Cevidoplenib is a selective spleen tyrosine kinase (Syk) inhibitor, offering potential anti-inflammatory and immunomodulatory effects. This compound impedes B cell receptor (BCR)-mediated survival, proliferation, and differentiation of B cells, making it useful in research focused on immune responses and related disorders. Additionally, Cevidoplenib demonstrates inhibitory activity on multiple kinases, including Jak2, Jak3, and RET, with varying degrees of potency, providing a versatile tool for investigating kinase signaling pathways in cellular biology.

Cat. No.

A84726

CAS No.

622387-85-3

OXSI-2

OXSI-2 is a potent Syk inhibitor that exhibits a bioavailable and cell-permeable profile, with an EC50 value of 313 nM and an IC50 of 14 nM. This compound effectively modulates Syk activity, making it a valuable tool for studying signaling pathways in immune responses and cancer. OXSI-2 is suitable for research applications focused on elucidating the role of Syk in disease processes and therapeutic interventions.

Cat. No.

A84727

CAS No.

1800047-00-0

Lanraplenib succinate

Synonyms: GS-9876 succinate

Lanraplenib succinate is a highly selective, orally active SYK inhibitor with an IC50 of 9.5 nM. It targets SYK activity in platelets through the glycoprotein VI (GPVI) receptor, demonstrating potential therapeutic effects in inflammatory diseases. Notably, Lanraplenib succinate does not prolong bleeding time in preclinical models, indicating a favorable safety profile for clinical applications.

Cat. No.

A84728

CAS No.

2043659-93-2

Cevidoplenib dimesylate

Synonyms: SKI-O-703 dimesylate

Cevidoplenib dimesylate is a selective inhibitor of spleen tyrosine kinase (Syk), demonstrating potential in modulating inflammatory and immune responses. This compound is primarily utilized in research focused on autoimmune diseases and allergic disorders, offering insights into the therapeutic mechanisms of Syk inhibition. Additionally, cevidoplenib may facilitate investigations into the role of Syk in various signaling pathways within the immune system.

Cat. No.

A84729

CAS No.

1204480-26-1

ER-27319 maleate

ER-27319 maleate is a selective inhibitor of spleen tyrosine kinase (SYK), effectively blocking its tyrosine phosphorylation and subsequent activity. This compound demonstrates significant biological activity by inhibiting the release of antigen-induced allergic mediators from both human and rat mast cells, with an IC50 value of 10 μM. ER-27319 maleate is valuable for research in allergic diseases and inflammation pathways.

Cat. No.

A84730

CAS No.

201010-95-9

ER-27319

ER-27319 is a potent and selective Spleen Tyrosine Kinase (SYK) inhibitor, known for its ability to suppress the tyrosine phosphorylation of SYK and thereby inhibit its enzymatic activity. This compound effectively blocks the release of antigen-induced allergic mediators from human and rat mast cells, exhibiting an IC50 of 10 μM. ER-27319 is a valuable tool for research in the field of allergic diseases, particularly in studies focused on mast cell activation and modulation.

Cat. No.

A84731

CAS No.

1491150-77-6

Syk-IN-1

Syk-IN-1 is a highly potent inhibitor of Syk (spleen tyrosine kinase), demonstrating an IC50 value of 35 nM. This compound effectively disrupts Syk-mediated signaling pathways, making it valuable for studies involving immune response, cell proliferation, and apoptosis. Syk-IN-1 is suitable for research applications focused on hematological malignancies and inflammatory diseases, facilitating the exploration of Syk's role in various biological processes.

Cat. No.

A84732

CAS No.

1312518-84-5

(R,S)-MK-8457

(R,S)-MK-8457 is a dual inhibitor of SYK and ZAP70, key signaling molecules involved in immune cell activation. This compound exhibits potent inhibitory activity, making it a valuable tool for investigating the pathophysiology of autoimmune disorders. Its application in research focuses primarily on the study of rheumatoid arthritis and other inflammatory conditions.

Cat. No.

A84733

CAS No.

1800046-97-2

Lanraplenib monosuccinate

Synonyms: GS-9876 monosuccinate

Lanraplenib monosuccinate is a highly selective inhibitor of spleen tyrosine kinase (SYK), with an IC50 of 9.5 nM. This compound inhibits SYK activity in platelets through the glycoprotein VI (GPVI) receptor, making it a promising candidate for the treatment of inflammatory diseases. Notably, lanraplenib monosuccinate does not prolong bleeding time in preclinical models, indicating a favorable safety profile for potential therapeutic applications.

Cat. No.

A84736

CAS No.

2568963-01-7

Syk-IN-8

Syk-IN-8 is a selective Syk inhibitor that exhibits significant antiproliferative activity against various hematological tumor cell lines. By targeting and inhibiting the phosphorylation of PLCγ2, Syk-IN-8 serves as a valuable tool for investigating the molecular mechanisms underlying blood cancers and evaluating potential therapeutic strategies. Its specificity and efficacy make it an important reagent for researchers focused on hematological malignancies.